Why is Merck stock surging today?

Merck's stock experienced a significant surge of 6.2% in pre-market trading after the company revealed positive results from Phase 3 INTerpath-001 trial. This trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with stage IIB-IV melanoma.

The trial involved 1,137 patients and marked the first large-scale confirmation of the mRNA-based individualized neoantigen therapy platform. This promising result came on the heels of positive actions from analysts such as Daiwa, which upgraded Merck to Outperform, and Wells Fargo, which issued a Buy rating. These upgrades reflected growing confidence in Merck's oncology and HIV pipeline, which is expected to de-risk the company's post-Keytruda patent cliff narrative.

The combination of the Phase 3 data and the upgrade cycle amplified the pre-market reaction, while the broader market showed little support, with the S&P 500 and Nasdaq only showing marginal gains or losses. Merck's peers, Pfizer and AbbVie, did not report similar catalysts today, making MRK a sector standout. The success of the Phase 3 INTerpath-001 trial strengthens the commercial case for the intismeran autogene platform across multiple tumor types and opens the door to additional Phase 3 studies in non-small cell lung cancer.